Ziprasidone in Adolescents with Autism: An Open-Label Pilot Study
- 1 December 2007
- journal article
- research article
- Published by Mary Ann Liebert Inc in Journal of Child and Adolescent Psychopharmacology
- Vol. 17 (6), 779-790
- https://doi.org/10.1089/cap.2006.0126
Abstract
Introduction: The antipsychotic drugs are the best-studied agents shown to reduce symptoms in autism, including hyperactivity, aggression, self-abusive behavior, temper tantrums, lability, irritability, social withdrawal, and stereotypical behaviors. However, significant weight gain has been associated with use of many atypical agents. Ziprasidone has been weight neutral in adult populations, but data from adolescents and patients with autism are sparse. However, ziprasidone administration has been associated with increases in the QTc. The purpose of this study was to collect pilot data on the efficacy and safety of ziprasidone in adolescents with autism, focusing on safety issues of weight gain and QTc. Methods: Twelve adolescents with autism (mean age 14.5 ± 1.8 years) were treated in a 6-week open pilot study. Ziprasidone dosage ranged from 20 to 160 mg/day (mean, 98.3 ± 40.4 mg/day). The primary efficacy measure was the Clinical Global Impressions–Improvement item (CGI-I); other efficacy measures included the Aberrant Behavior Checklist and the Children's Psychiatric Rating Scale. Results: Based on the CGI-I, 9 of 12 (75%) patients were treatment responders. Ziprasidone was weight neutral, and the QTc increased by a mean of 14.7 msec. Two subjects had acute dystonic reactions. Cholesterol decreased and prolactin remained the same. Conclusions: Ziprasidone shows promise as a treatment for adolescents with autism. More definitive trials are needed.Keywords
This publication has 25 references indexed in Scilit:
- Risperidone Treatment of Autistic Disorder: Longer-Term Benefits and Blinded Discontinuation After 6 MonthsAmerican Journal of Psychiatry, 2005
- Risperidone in the Treatment of Disruptive Behavioral Symptoms in Children With Autistic and Other Pervasive Developmental DisordersPEDIATRICS, 2004
- A Randomized Evaluation of the Effects of Six Antipsychotic Agents on QTc, In the Absence and Presence of Metabolic InhibitionJournal of Clinical Psychopharmacology, 2004
- Risperidone in Children with Autism and Serious Behavioral ProblemsThe New England Journal of Medicine, 2002
- Placebo-controlled acute dosage naltrexone study in young autistic childrenPsychiatry Research, 1995
- Measurement of the QT interval and the risk associated with QTc interval prolongation: A reviewThe American Journal of Cardiology, 1993
- Factor validity and norms for the Aberrant Behavior Checklist in a community sample of children with mental retardationJournal of Autism and Developmental Disorders, 1992
- Behavioral Effects of Haloperidol in Young Autistic Children: An Objective Analysis Using a Within-Subjects Reversal DesignJournal of the American Academy of Child Psychiatry, 1980
- A RATING SCALE FOR EXTRAPYRAMIDAL SIDE EFFECTSActa Psychiatrica Scandinavica, 1970